Effects of Topical Hyaluronic Acid Gel on Postoperative Pain and Wound Healing
Clinical Study to Evaluate the Effects of a Topical Hyaluronic Acid (HA) Gel on Postoperative Pain and Wound Healing at Palatal Donor Sites in Subjects Undergoing Mucogingival Procedures
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Marcelo Faveri, DDS, PhD
- Phone Number: 551198644-9962
- Email: mdfaveri@uol.com.br
Study Locations
-
-
São Paulo
-
Guarulhos, São Paulo, Brazil, 04081-010
- Faveri Academy
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and females, between 18-70 years of age
- Informed Consent Form signed and availability for the duration of the study
- Good general health (absence of any condition that, in the opinion of the Principal Investigator, might constitute a risk to the subject while participating in the study
- Clinical indication for mucogingival surgery that requires a de-epithelialized gingival graft (DGG) from the palate
- Willingness to provide information related to their medical history
- Minimum of 10 uncrowned permanent natural teeth (excluding third molars)
- Normal salivary flow
Exclusion Criteria:
- Oral pathology, chronic disease, or a history of allergy to testing products
- Subject using anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti-inflammatory medication or daily analgesics within one month prior to the start of the study or scheduled to start such intake during the course of the study
- Subject participating in any other clinical study
- Subject pregnant or breastfeeding
- Subject allergic to oral care products, personal care consumer products, or their ingredients
- Extended use of antibiotics or therapeutic mouthwash any time during the three months prior to entry into the study
- A medical history reporting that the subject has a current systemic or autoimmune disease, such as diabetes, lupus, etc
- Ongoing use of medications known to affect the gingival tissues (i.e. calcium channel blockers, phenytoin, cyclosporine)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group I
A gel containing Hyaluronic acid in combination with a hemostatic sponge
|
Hyaluronic acid and hemostatic sponge
|
|
Active Comparator: Group II
A hemostatic sponge alone
|
Hemostatic sponge
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wound healing area
Time Frame: Baseline
|
Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter
|
Baseline
|
|
Wound healing area
Time Frame: 3 days after surgery
|
Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter
|
3 days after surgery
|
|
Wound healing area
Time Frame: 7 days after surgery
|
Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter
|
7 days after surgery
|
|
Wound healing area
Time Frame: 14 days after surgery
|
Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter
|
14 days after surgery
|
|
Wound healing area
Time Frame: 21 days after surgery
|
Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter
|
21 days after surgery
|
|
Wound healing area
Time Frame: 42 days after surgery
|
Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter
|
42 days after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain assessment
Time Frame: Baseline
|
Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery.
A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt".
The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded.
|
Baseline
|
|
Pain assessment
Time Frame: 3 days after surgery
|
Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery.
A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt".
The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded.
|
3 days after surgery
|
|
Pain assessment
Time Frame: 7 days after surgery
|
Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery.
A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt".
The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded.
|
7 days after surgery
|
|
Pain assessment
Time Frame: 14 days after surgery
|
Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery.
A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt".
The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded.
|
14 days after surgery
|
|
Pain assessment
Time Frame: 21 days after surgery
|
Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery.
A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt".
The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded.
|
21 days after surgery
|
|
Pain assessment
Time Frame: 42 days after surgery
|
Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery.
A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt".
The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded.
|
42 days after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Marcelo Faveri, DDS, PhD, Faveri Academy
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRO-2022-09-WH-BZ-ZM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.